To investigate the contribution of RTK inhibition to activity of innate immune response pathways in MLL1-rearranged AML, we performed RNA-Seq of LIN− bone marrow cells from secondary recipients 8 weeks after initiating treatment with chemotherapy, RTK inhibitor, or both. The gene discussed is KMT2A; the disease is acute myeloid leukemia.